Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HMBD-001 in combination with cetuximab with or without docetaxel in advanced squamous cell carcinoma
CTR20262329Phase 2Active
- Sponsor
- Harvest Medical
- Start
- Aug 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hmbd-001, cetuximab, docetaxel in Nonhematologic neoplasms, squamous cell carcinoma (SCC), Pulmonary squamous cell carcinoma, head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Harvest Medical. Started Aug 2026; status: active.
02
Drugs
hmbd-001cetuximabdocetaxel
03
Conditions
Nonhematologic neoplasmssquamous cell carcinoma (SCC)Pulmonary squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20262329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262329.